Developing blood tests using RNA modifications to screen for cancer
Late cancer diagnosis limits treatment options. Many cancers can be cured when diagnosed at the earliest stages of tumour development, making accurate early detection an important clinical need.
Cyberna is developing blood tests that measure chemical modifications of RNA to detect early cancer signals. Its platform combines mass spectrometry and machine learning to identify biomarker signatures, with colorectal cancer screening among its intended uses.
What stands out about Cyberna
Partners with IRCM on EPIcs to develop RNA-based approaches to early pancreatic cancer detection through Companies and Campus 2024/2025.
Co-founded by Eric Rivals, a CNRS research director who helped develop EpiTransDiag's RNA-based cancer detection approach.
Won selection as a 2025 Boost Invest MedVallée laureate, gaining investor access, expert support and fundraising visibility.
Raised financing from Paris-Saclay Business Angels in 2026.
Won the i-Lab 2024 innovation competition for its cancer diagnostic technology.
Co-founder Patrice Garnier previously co-founded Meletios Therapeutics, where he has served as chairman since 2020.
Emerged from EpiTransDiag, an academic RNA-diagnostics project involving CNRS, Inserm and Montpellier university and hospital teams.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.